Şunu aradınız:: immunosuppressjoni (Maltaca - İngilizce)

immunosuppressjoni
immunosuppression

immunosuppressjoni sistemika
systemic immunosuppression

immunosuppressjoni eċċessiva b’ riskju ta ’ mard limfoproliferattiv.
excessive immunosuppression with risk of lymphoproliferative disease.

qed jirċievu kemoterapija, trattament bir- radjazzjoni jew immunosuppressjoni.
are receiving chemotherapy, radiation treatment or immunosuppression;

jekk qed tingħata kemoterapija, trattament bir-radjazzjoni jew immunosuppressjoni.
if you are receiving chemotherapy, radiation treatment or immunosuppression.

- jekk qed jirċievu kemoterapija, trattament bir- radjazzjoni jew immunosuppressjoni.
- if you are receiving chemotherapy, radiation treatment or immunosuppression

li qed jieħdu l-kemoterapija, trattament ta’ radjazzjoni jew immunosuppressjoni.
receiving chemotherapy, radiation treatment or immunosuppression.

infezzjonijiet ġeneralment assoċjati ma’ immunosuppressjoni kienu nnutati fil-klieb.
infections generally associated with immunosuppression were noted in dogs.

ciclosporin, tacrolimus: immunosuppressjoni eċċessiva b’riskju ta’ mard limfoproliferattiv.
ciclosporin, tacrolimus: excessive immunosuppression with risk of lymphoproliferative disease.

komuni ħafna: immunosuppressjoni * rari: graft-versus-host-disease
very common: immunosuppression * rare: graft-versus-host disease *

attivazzjoni mill-ġdid tal-infezzjonijiet hija reazzjoni mistennija matul perijodi ta’ immunosuppressjoni.
reactivation of infection is an expected reaction during periods of immunosuppression.

jeħtieġ li tieħu advagraf kuljum sakemm ikollok bżonn immunosuppressjoni biex tipprevjeni rifjut tal-organu trapjantat tiegħek.
you will need to take advagraf every day as long as you need immunosuppression to prevent rejection of your transplanted organ.

għandek bżonn li tieħu modigraf kuljum sakemm għandek bżonn immunosuppressjoni biex tipprevjeni riġettar tal-organu trappjantat tiegħek.
you will need to take modigraf every day as long as you need immunosuppression to prevent rejection of your transplanted organ.

il-mijelosuppressjoni u l-immunosuppressjoni kienu l-effetti terapewtiċi mixtieqa tar-regimen kondizzjonarju.
myelo-suppression and immuno-suppression were the desired therapeutic effects of the conditioning regimen.

Ġie rrapportat li t-twaqqif tal-immunosuppressjoni jista' jipprovdi rigressjoni parzjali tad-disturb limfoproliferattiv.
it has been reported that discontinuation of immunosuppression may provide partial regression of the lymphoproliferative disorder.

hps hi kundizzjoni rari li kienet deskritta b’rabta ma’ infezzjonijiet, immunosuppressjoni u varjetà ta’ mardiet awtoimmuni.
hps is a rare condition that has been described in association with infections, immunosuppression and a variety of autoimmune diseases.

wara l- kura b’ advagraf ġie li ġew rapportati tumuri beninji u malinji bħala riżultat ta ’ l- immunosuppressjoni.
benign and malignant tumours have been reported following advagraf treatment as a result of immunosuppression.

protopic m'għandux jintuża f'pazjenti b`immunodefiċjenza konġenitali jew akkwistati jew f'pazjenti fuq terapija li tikkawza immunosuppressjoni.
protopic should not be used in patients with congenital or acquired immunodeficiencies or in patients on therapy that cause immunosuppression.

ir-riżultati preliminari juru li immunosuppressjoni sistemika wara li tinbeda l-kura b’nivolumab ma jidhirx li tipprekludi r-rispons fuq nivolumab.
the preliminary results show that systemic immunosuppression after starting nivolumab treatment does not appear to preclude the response on nivolumab.

il-każijiet l-oħra huma taħlita ta’ tumuri differenti u jinkludu tumuri rari li huma assoċjati s-soltu ma’ immunosuppressjoni.
the other cases represented a variety of different malignancies and included rare malignancies usually associated with immunosuppression.